Migliari R, Muscas G, Melis M, Garau M, Sorgia M, Scarpa R M, Usai E
Clinica Urologica Università degli Studi di Cagliari.
Arch Ital Urol Nefrol Androl. 1991 Mar;63(1):155-61.
This study evaluates the sleep-related erections in 5 patients with locally advanced prostate cancer (T3NOMO) during 6 months treatment with Casodex by multinight continuous monitoring of penile tumescence and rigidity. Mean serum LH, Testosterone and Estradiol levels shown a no statistically significant increase at the six months control. We found no significant modifications in the number of NPT episodes, maximum penile circumference and rigidity time before and after therapy. Penile arterial flow and neurologic examination were also unmodified. All patients had a stable disease and unchanged performance status after 6 months. This pure antiandrogen in a men with prostate cancer does not seem to interfere with self reported libido and erectile capability.
本研究通过对阴茎肿胀和硬度进行多晚连续监测，评估了5例局部晚期前列腺癌（T3N0M0）患者在接受6个月的康士得治疗期间与睡眠相关的勃起情况。在六个月的对照期，平均血清促黄体生成素、睾酮和雌二醇水平无统计学意义上的显著升高。我们发现治疗前后夜间阴茎勃起（NPT）次数、最大阴茎周长和硬度时间均无显著变化。阴茎动脉血流和神经学检查也未改变。6个月后，所有患者病情稳定，身体状况未变。这种单纯的抗雄激素药物在前列腺癌男性患者中似乎不会干扰自我报告的性欲和勃起能力。
